Mizuho Securities analyst Salim Syed maintained a Buy rating on Coherus Biosciences (CHRS – Research Report) today and set a price target of $21.00. The company’s shares closed today at $6.55.
According to TipRanks, Syed is an analyst with an average return of -17.3% and a 35.40% success rate. Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $18.60 average price target, which is a 183.97% upside from current levels. In a report released on November 14, Maxim Group also assigned a Buy rating to the stock with a $15.00 price target.
See the top stocks recommended by analysts >>
CHRS market cap is currently $513.3M and has a P/E ratio of -1.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Read More on CHRS: